Veronika Sanin

Veronika Sanin

Auto-generated profile, based on publicly available information

Veronika Sanin

Department of Cardiology, Deutsches Herzzentrum München, Klinikum der Technischen Universität München, German Heart Center Munich, Klinik für Herz- und Kreislauferkrankungen , Lazarettstr. 36, Munich D-80636

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in European Journal of Public Health
Verified
Journal Article
Open access
PDF file
VSVeronika Sanin
Veronika Sanin
RSRaphael Schmieder
Raphael Schmieder
SASara Ates
Sara Ates
LSLea Dewi Schlieben
Lea Dewi Schlieben
JWJens Wiehler
Jens Wiehler
HSHeribert Schunkert
Heribert Schunkert
Background: Heterozygous familial hypercholesterolemia (FH) represents the most frequent monogenic disorder with an estimated prevalence of 1:250 in the general population. Diagnosis during childhood enables early initiation of preventive measures, reducing the risk of severe consecutive atherosclerotic manifestations. Nevertheless, population-based screening programs for FH are scarce. Methods: In the VRONI study, children aged 5–14 years in Bavaria are invited to participate in an FH screening program during regular pediatric visits. The screening is based on low-density lipoprotein cholesterol measurements from capillary blood. If exceeding 130 mg/dl (3.34 mmol/l), i.e. the expected 95th percentile in this age group, subsequent molecular genetic analysis for FH is performed. Children with FH pathogenic variants enter a registry and are treated by specialized pediatricians. Furthermore, qualified training centers offer FH-focused training courses to affected families. For first-degree relatives, reverse cascade screening is recommended to identify and treat affected family members. Results: Implementation of VRONI required intensive prearrangements for addressing ethical, educational, data safety, legal and organizational aspects, which will be outlined in this article. Recruitment started in early 2021, within the first months, more than 380 pediatricians screened over 5200 children. Approximately 50 000 children are expected to be enrolled in the VRONI study until 2024. Conclusions: VRONI aims to test the feasibility of a population-based screening for FH in children in Bavaria, intending to set the stage for a nationwide FH screening infrastructure. Furthermore, we aim to validate genetic variants of unclear significance, detect novel causative mutations and contribute to polygenic risk indices (DRKS00022140; August 2020).

25 May 2026 in European Heart Journal
Verified
Journal Article
Open access
AWAlbert Wiegman
Albert Wiegman
MBMafalda Bourbon
Mafalda Bourbon
TFTomas Freiberger
Tomas Freiberger
SGSamuel Gidding
Samuel Gidding
SGSusanne Greber-Platzer
Susanne Greber-Platzer
JLJeanine elisabeth roeters Roeters van Lennep
Jeanine elisabeth roeters Roeters van Lennep
Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated LDL cholesterol (LDL-C) concentrations. FH exists in two forms: heterozygous FH (HeFH), which affects around 1 in 300 people worldwide, and homozygous FH (HoFH), which affects around 1 in 300 000. Individuals with FH are at increased risk of premature atherosclerotic cardiovascular disease (ASCVD) and death, and those with HoFH are, if untreated, at extreme risk of ASCVD manifestations even before adulthood. Early diagnosis and treatment in childhood can extend or normalize life expectancy, but limited awareness, underdiagnosis, and undertreatment remain major challenges. This consensus statement aims to address these challenges, supported by increased knowledge of the pathogenesis of FH and the availability of an increasing range of lipid-lowering therapies (LLTs) that can be used from early ages. To increase the detection rate of FH, all countries are encouraged to establish a paediatric screening programme and, given that current diagnostic criteria often fail to identify children with an FH-causing genetic variant, revised diagnostic criteria are presented. Updated LDL-C treatment goals are proposed, and the importance of starting LLTs before puberty in children with HeFH, and, if needed, from 6 years, is highlighted. Guidance on how to manage FH is provided, including treatment algorithms for use in children with either HeFH or HoFH and a discussion on how to promote a smooth transition to adult care. Early detection and optimal treatment as advocated in this consensus statement are crucial to improving life expectancy for children and adolescents with FH.


20 May 2017 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
VSVeronika Sanin
Veronika Sanin
VPVanessa Pfetsch
Vanessa Pfetsch
WKWolfgang Koenig
Wolfgang Koenig

9 July 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
RSRaphael S Schmieder
Raphael S Schmieder
JKJohannes Krefting
Johannes Krefting
SASara Ates
Sara Ates
LSLea Dewi Schlieben
Lea Dewi Schlieben
SAStefan Arens
Stefan Arens
VSVeronika Sanin
Veronika Sanin
Aims: The study aimed to assess the effectiveness of three clinical diagnostic criteria [Simon Broome (SB), MEDPED (MP), and guideline-derived (GL-EAS)] in identifying children with familial hypercholesterolaemia (FH) compared with genetic testing. The evaluation involved 1337 children with elevated LDL cholesterol (LDL-C) levels, focusing on the sensitivity and specificity of these clinical scores in detecting genetically confirmed FH cases. Methods and results: Clinical data were gathered by a self-reporting questionnaire. Clinical FH was defined in accordance with the tested FH score. Genetically confirmed heterozygous FH (HeFH) was defined by a (likely) pathogenic variant. Of the 1337 children undergoing genetic analysis, 211 showed a pathogenic FH mutation. Applying SB, MP, and GL-EAS criteria resulted in 210/1337, 125/1337, and 112/835 children being categorized to have FH clinically. The sensitivity of the clinical scores ranged from 0.44 to 0.54 with a positive predictive value (PPV) of 0.51–0.79. The specificity was 0.91–0.97 with a negative predictive value (NPV) of 0.89–0.91. Similar results were observed for the three clinical scores regarding sensitivity, specificity, PPV, and NPV in subgroup analyses defined by gender, age (<10 years vs. ≥10 years), or weight [≥90th BMI (body mass index) percentile vs. <90th BMI percentile]. Conclusion: Clinical FH scores offer a high degree of specificity for FH diagnosis in children, but at the expense of low sensitivity. Specifically, half of the mutation-positive children in this study would have been missed for early diagnosis and preventive treatment. Given the widespread availability of affordable genetic testing, such analysis should be performed at a lower threshold than that indicated by these clinical scores.

20 February 2024 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
VSVeronika Sanin
Veronika Sanin
RSRaphael S Schmieder
Raphael S Schmieder
WKWolfgang Koenig
Wolfgang Koenig
Veronika Sanin, MD, Raphael S Schmieder, MD, Wolfgang Koenig, MD; Early action, lifelong impact: The crucial role of early detection, risk stratification and ag